Hamburg, Germany, 27 October 2025: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced that the Company has received a payment of $25 million from Bristol Myers Squibb (NYSE: BMY) for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners’ joint pipeline of programs aimed at tackling neurogenerative diseases.

Launched in 2016, the collaboration focuses on discovering and developing disease-modifying treatments for neurodegenerative diseases, where current treatment options remain limited. Since then, the companies have built a strong pipeline of innovative programs, including EVT8683, in-licensed by Bristol Myers Squibb in 2021 as BMS-986419, that has completed Phase 1 clinical trials. The partnership was extended in 2023 for an additional eight years, reflecting the shared commitment to bringing transformative treatments into the clinic.

Cord Dohrmann, Chief Scientific Officer of Evotec, commented, “Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases.”